Four months after a court froze the vaccine schedule, the US still has no functioning ACIP
The appeal is moving on an expedited track, with a status report due this month. But CIDRAP's vaccine-policy trackers make a pointed argument: a working committee could exist right now, if HHS chose to seat one.
It has been just under four months since a federal court in Massachusetts stayed the Advisory Committee on Immunization Practices' reconstituted membership and the childhood vaccine schedule it produced. As of early July, the practical result of that stay has not changed: the United States still does not have a functioning ACIP [s1].
That is not, according to a 9 July tracking update from CIDRAP, an unavoidable consequence of the litigation. It is a choice [s1].
Where the case stands
The underlying lawsuit, brought by medical and public health organizations against the Secretary of Health and Human Services, continues on two parallel tracks. An appeal of the March stay is moving through the First Circuit Court of Appeals on an expedited schedule, with briefs being exchanged faster than in ordinary appellate litigation [s1]. Separately, the district court that issued the original stay is running its own schedule, with a joint status report and additional briefing due from the parties this month [s1].
Neither track has produced a ruling on the merits since the March stay itself. Both are procedural machinery grinding forward without, so far, changing the operative fact on the ground: the appointments of the thirteen ACIP members named since June 2025 remain stayed, as does the schedule those appointments helped produce.
The argument that the vacancy is a choice
CIDRAP's framing is worth stating precisely, because it separates two questions that are easy to collapse into one. The first question is legal: who has the authority to appoint ACIP members and under what process, which is what the litigation is actually about. The second is operational: whether a functioning committee could exist while that legal question remains unresolved.
CIDRAP's answer to the second question is that a committee could be seated "relatively soon if appropriately qualified members were placed on the committee through the standard vetting process" — and that the absence of a quorum does not, in fact, hinge on the outcome of the case [s1]. In other words, HHS retains the ability to nominate and seat ACIP members through the ordinary process even while litigation over the prior, stayed appointments continues. That it has not done so is a decision, not a legal constraint imposed by the court.
Why an empty committee is not a neutral default
ACIP's absence is not simply a paperwork gap. The committee's recommendations are the mechanism through which new vaccines and changed dosing schedules become eligible for the protections and funding streams built around them — private insurance coverage requirements under the Affordable Care Act, the Vaccines for Children program that supplies roughly half of US children with immunizations, and many state school-entry requirements all reference ACIP's recommendations directly or through mechanisms built on them.
With no functioning committee, none of those downstream processes can act on new evidence. A vaccine approved by FDA during this period has no advisory body positioned to recommend it, place it into the immunization schedule, or trigger the coverage obligations that recommendation activates. The system is not paused so much as it is running on whatever recommendations were last validly in place before the disputed reconstitution — which is precisely what the March stay was designed to preserve, and precisely why both sides in the litigation treat the appointment question as high-stakes rather than procedural.
What the July deadlines actually are
Beyond the court filings, CIDRAP's July tracking flags several other dates converging this month: a White House public comment period on federal science funding closing 13 July; a Senate HELP Committee confirmation hearing for the administration's CDC director nominee on 15 July; and the end of the Massachusetts legislative session on 31 July, relevant to a pending state bill on religious vaccine exemptions [s1]. None of these directly resolves the ACIP vacancy, but each touches the broader institutional environment the litigation is playing out in.
What to watch
Whether the joint status report due this month signals a settlement posture, continued litigation, or an attempt by HHS to moot part of the case by seating a new committee through an uncontested process. Whether the First Circuit's expedited schedule produces a ruling before the district court proceedings conclude, and which court's decision ultimately controls. And separately from the legal questions entirely: whether HHS exercises the appointment authority CIDRAP says remains available to it, seating a committee independent of how the litigation resolves. This article describes the status of ongoing litigation and institutional process; it is not legal or medical advice.
Sources
- [s1] CIDRAP, "Still No ACIP Quorum, Collapsing Lawsuits, and Vaccine Questions Answered: The State of US Vaccine Policy," 9 July 2026. https://www.cidrap.umn.edu/adult-non-flu-vaccines/still-no-acip-quorum-collapsing-lawsuits-and-vaccine-questions-answered
Sources
A federal court froze the 2026 childhood vaccine schedule. Who writes it is the fight.
The advisory committee that shaped U.S. immunization policy for decades was replaced, then bypassed. In March a judge stayed the result.
CDC posts a new ACIP charter that drops the vaccine-expertise requirement
The committee's founding document now asks for a 'balanced range' of expertise rather than vaccine-specific knowledge, and adds review of non-vaccine alternatives to its mandate.
A judge stayed the reconstituted CDC vaccine panel and its January schedule changes
Judge Brian Murphy found the government likely broke two federal laws when it bypassed ACIP and replaced its members. The ruling reverts the childhood schedule and cancels this week's ACIP meeting.
Pediatricians published their own vaccine schedule, and it no longer matches CDC's
The American Academy of Pediatrics' 2026 schedule covers 18 diseases and carries 12 outside endorsements. The federal schedule signed three weeks earlier lists 11 vaccines for all children.